Trial Profile

A phase 2 double-blind, randomized study of COYA 301 in patients with mild to moderate AD

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2025 According to a Coya Therapeutics media release, company announced that the principal investigator of this study Alireza Faridar, M.D will be presenting data from his study at the ADPD 2025 conference in Vienna.
18 Mar 2025 According to a Coya Therapeutics media release, Additional single cell proteomics data from the completed investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer disease is expected in second half of 2025.
06 Feb 2025 According to a Coya Therapeutics media release, the company has announced encouraging blood biomarker data from this study and comprehensive dataset from this study will be presented and released throughout 2025 and in a peer reviewed publication.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com